Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of ...

Simulations Plus, Inc. (SLP) reported third-quarter fiscal 2025 adjusted earnings of 45 cents per share, which expanded 66.7% year over year. The figure also surpassed the Zacks Consensus Estimate of ...

Simulations Plus, Inc.SLP was a big mover last session, as the company saw its shares rise nearly 6% on the day. Shares gained after the company reported higher earnings and revenues for the third ...

Screen: Pro-ficiency creates clinical trial simulations, filling a gap for the Simulations Plus suite of products. So far, 2024 is shaping up to be a banner year for Simulations Plus Inc. The ...

The company's recent performance was broadly in line with expectations; however, if its guidance is accurate, revenue and profitability could rise this fiscal year. For its fiscal fourth quarter of ...

SUMMARY Simulations Plus(NASDAQ:SLP) reported mixed operational results for Q3 FY2025, as inorganic revenue gains from acquisitions were offset by organic decline and profitability was burdened by a ...

Simulations Plus faces soft revenue growth in the short term, due largely to macro conditions. The negatives appear to have been priced in, though, after a period of significant share price declines.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods ...